Drug Profile
Arbaclofen extended release - RVL Pharmaceuticals
Alternative Names: Arbaclofen extended release tablets (AERT) - RVL Pharmaceuticals; Ontinua ER; OS-440Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Osmotica Pharmaceutical
- Developer RVL Pharmaceuticals
- Class Aminobutyric acids; Behavioural disorder therapies; Gastrokinetics; Muscle relaxants; Small molecules
- Mechanism of Action GABA B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Muscle spasticity
- No development reported Opioid-related disorders